Intended use
Support patient selection and response prediction for anti-PD1/PD-L1 treatment decisions.
MIORG’s current portfolio includes a development-stage prognostication test and a preclinical antibody program designed to address the challenge of immunotherapy resistance.
Pair better patient selection with mechanism-led combination thinking.
MIORG's predictive immune profiling concept uses immune functional RNA/DNA profiling to improve prediction of patient response to anti-PD1/PD-L1 immune checkpoint therapies. It integrates a focused immune-related gene signature with tumor mutational burden for a more complete view of immune readiness than conventional single-marker approaches.
Support patient selection and response prediction for anti-PD1/PD-L1 treatment decisions.
Immune-related gene signature combined with tumor mutational burden and translational interpretation.
Improve stratification, reduce uncertainty, and support earlier consideration of alternative pathways.
Development and validation stage, with positioning for clinically relevant partnership pathways.
Tumors may evade checkpoint therapy by suppressing innate immune activity and limiting the generation of new antitumor T cells. In this context, checkpoint blockade alone may not be sufficient to restore productive immune control.
MIO-36 is a therapeutic antibody program designed to increase tumor immunogenicity and help generate antitumor T cells, improving the effect of anti-PD1/PD-L1 therapy in resistant tumor models.
Increase tumor immunogenicity to improve downstream T-cell generation.
Designed for use alongside anti-PD1/PD-L1 strategies rather than as a standalone checkpoint alternative.
Preclinical program with resistant model evidence presented as early validation, not clinical proof.
Relevant to biopharma groups interested in resistance modulation and combination immunotherapy design.